[144] Bitwise MARA Option Income Strategy ETF SEC Filing

Rhea-AI Filing Summary

Form 144 notice for proposed sale of Enliven Therapeutics common stock. The filer plans to sell 20,001 shares through Jefferies LLC with an aggregate market value of $403,020.15, to be executed on or about 09/08/2025 on Nasdaq. The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics. The filer reported two prior sales in the past three months totaling 13,334 shares with gross proceeds of $253,566.41. The form includes the standard representation that the seller is unaware of undisclosed material adverse information.

Insights

Securities Analyst

TL;DR Insiders are filing to sell a small portion of outstanding shares; transaction appears routine and disclosed via Form 144.

The notice details a proposed sale of 20,001 founder shares through Jefferies with an indicated market value of $403,020.15 and an approximate sale date of 09/08/2025. The filer previously sold 6,667 shares on 07/07/2025 and 6,667 shares on 08/07/2025, suggesting ongoing, incremental dispositions. Relative to the reported 59,000,000 shares outstanding, the planned sale is immaterial on a percentage basis. The filing meets Rule 144 disclosure requirements and provides acquisition and payment details needed for market transparency.

Corporate Governance Expert

TL;DR Governance process followed: insider attestation present and broker identified; no material red flags in the notice itself.

The submission includes the required attestation that the seller lacks undisclosed material adverse information and names Jefferies LLC as the broker. The shares were identified as founder shares acquired on 09/01/2019 from Enliven Therapeutics. Recent prior sales are disclosed with dates and gross proceeds. Absent additional context on timing or insider plans, the document is a routine disclosure rather than a governance concern.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	20001	403020.15	59000000	09/08/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/01/2019	Founder Shares	Enliven Therapeutics			20001	09/01/2019	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Anish Patel 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	07/07/2025	6667	131950.73
Anish Patel 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	08/07/2025	6667	121615.68

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many shares is the filer proposing to sell in the IMRA Form 144?

The filer proposes to sell 20,001 shares of common stock.

Which broker is handling the proposed sale noted in the Form 144?

The broker listed is Jefferies LLC, 520 Madison Ave, New York, NY.

What is the aggregate market value and approximate sale date reported?

Aggregate market value is $403,020.15 with an approximate sale date of 09/08/2025 on Nasdaq.

When were the securities to be sold originally acquired according to the filing?

The shares were acquired as founder shares on 09/01/2019 from Enliven Therapeutics.

What sales by the filer occurred in the past three months per the form?

Two sales are reported: 6,667 shares on 07/07/2025 for $131,950.73 and 6,667 shares on 08/07/2025 for $121,615.68.